Glomerular hypertension and hyperperfusion in progressive renal disease

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Systemic hypertension is both cause and consequence of renal disease. Recent animal studies suggest that the adverse effects of systemic hypertension on the progression of renal disease may depend upon the intra-glomerular hemodynamic consequences. Systemic hypertension accompanied by afferent arteriolar vasoconstriction is associated with normal glomerular capillary pressure, and relative protection against morphologic injury. In contrast, systemic hypertension with afferent arteriolar vasodilatation leads to glomerular hypertension, and is associated with structural injury. Glomerular hypertension may be present even in the setting of normal systemic pressure, as in experimental diabetes. Therapeutic interventions that attenuate glomerular capillary hypertension slow the development of glomerular injury.Dietary protein restriction, which normalizes glomerular capillary filtration, perfusion, and pressure without lowering blood pressure, retards the development of glomerular sclerosis. Alternatively, selective reduction of glomerular capillary pressure with converting enzyme inhibitor therapy is also protective against progressive renal injury. In contrast, antihypertensive therapy that controls systemic hypertension but does not reduce glomerular capillary pressure fails to protect remnant kidney rats from glomerular injury. These studies suggest that control of glomerular hypertension may be of special benefit to the patient with progressive renal disease.

Original languageEnglish (US)
Pages (from-to)S14-S18
JournalJournal of Cardiovascular Pharmacology
Volume10
StatePublished - 1987
Externally publishedYes

Fingerprint

Hypertension
Kidney
Pressure
Wounds and Injuries
Enzyme Therapy
Dietary Proteins
Sclerosis
Enzyme Inhibitors
Vasoconstriction
Vasodilation
Antihypertensive Agents
Disease Progression
Perfusion
Hemodynamics
Blood Pressure
Therapeutics

Keywords

  • Chronic renal failure
  • Converting enzyme inhibitor
  • Glomerular sclerosis
  • Hypertension
  • Proteinuria

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology

Cite this

Glomerular hypertension and hyperperfusion in progressive renal disease. / Anderson, Sharon.

In: Journal of Cardiovascular Pharmacology, Vol. 10, 1987, p. S14-S18.

Research output: Contribution to journalArticle

@article{fbd73712eedb4b5faa272304ff8457d4,
title = "Glomerular hypertension and hyperperfusion in progressive renal disease",
abstract = "Systemic hypertension is both cause and consequence of renal disease. Recent animal studies suggest that the adverse effects of systemic hypertension on the progression of renal disease may depend upon the intra-glomerular hemodynamic consequences. Systemic hypertension accompanied by afferent arteriolar vasoconstriction is associated with normal glomerular capillary pressure, and relative protection against morphologic injury. In contrast, systemic hypertension with afferent arteriolar vasodilatation leads to glomerular hypertension, and is associated with structural injury. Glomerular hypertension may be present even in the setting of normal systemic pressure, as in experimental diabetes. Therapeutic interventions that attenuate glomerular capillary hypertension slow the development of glomerular injury.Dietary protein restriction, which normalizes glomerular capillary filtration, perfusion, and pressure without lowering blood pressure, retards the development of glomerular sclerosis. Alternatively, selective reduction of glomerular capillary pressure with converting enzyme inhibitor therapy is also protective against progressive renal injury. In contrast, antihypertensive therapy that controls systemic hypertension but does not reduce glomerular capillary pressure fails to protect remnant kidney rats from glomerular injury. These studies suggest that control of glomerular hypertension may be of special benefit to the patient with progressive renal disease.",
keywords = "Chronic renal failure, Converting enzyme inhibitor, Glomerular sclerosis, Hypertension, Proteinuria",
author = "Sharon Anderson",
year = "1987",
language = "English (US)",
volume = "10",
pages = "S14--S18",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Glomerular hypertension and hyperperfusion in progressive renal disease

AU - Anderson, Sharon

PY - 1987

Y1 - 1987

N2 - Systemic hypertension is both cause and consequence of renal disease. Recent animal studies suggest that the adverse effects of systemic hypertension on the progression of renal disease may depend upon the intra-glomerular hemodynamic consequences. Systemic hypertension accompanied by afferent arteriolar vasoconstriction is associated with normal glomerular capillary pressure, and relative protection against morphologic injury. In contrast, systemic hypertension with afferent arteriolar vasodilatation leads to glomerular hypertension, and is associated with structural injury. Glomerular hypertension may be present even in the setting of normal systemic pressure, as in experimental diabetes. Therapeutic interventions that attenuate glomerular capillary hypertension slow the development of glomerular injury.Dietary protein restriction, which normalizes glomerular capillary filtration, perfusion, and pressure without lowering blood pressure, retards the development of glomerular sclerosis. Alternatively, selective reduction of glomerular capillary pressure with converting enzyme inhibitor therapy is also protective against progressive renal injury. In contrast, antihypertensive therapy that controls systemic hypertension but does not reduce glomerular capillary pressure fails to protect remnant kidney rats from glomerular injury. These studies suggest that control of glomerular hypertension may be of special benefit to the patient with progressive renal disease.

AB - Systemic hypertension is both cause and consequence of renal disease. Recent animal studies suggest that the adverse effects of systemic hypertension on the progression of renal disease may depend upon the intra-glomerular hemodynamic consequences. Systemic hypertension accompanied by afferent arteriolar vasoconstriction is associated with normal glomerular capillary pressure, and relative protection against morphologic injury. In contrast, systemic hypertension with afferent arteriolar vasodilatation leads to glomerular hypertension, and is associated with structural injury. Glomerular hypertension may be present even in the setting of normal systemic pressure, as in experimental diabetes. Therapeutic interventions that attenuate glomerular capillary hypertension slow the development of glomerular injury.Dietary protein restriction, which normalizes glomerular capillary filtration, perfusion, and pressure without lowering blood pressure, retards the development of glomerular sclerosis. Alternatively, selective reduction of glomerular capillary pressure with converting enzyme inhibitor therapy is also protective against progressive renal injury. In contrast, antihypertensive therapy that controls systemic hypertension but does not reduce glomerular capillary pressure fails to protect remnant kidney rats from glomerular injury. These studies suggest that control of glomerular hypertension may be of special benefit to the patient with progressive renal disease.

KW - Chronic renal failure

KW - Converting enzyme inhibitor

KW - Glomerular sclerosis

KW - Hypertension

KW - Proteinuria

UR - http://www.scopus.com/inward/record.url?scp=0342376006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0342376006&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - S14-S18

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

ER -